Small Cell Lung Carcinoma
"Small Cell Lung Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
Descriptor ID |
D055752
|
MeSH Number(s) |
C04.588.894.797.520.109.220.624 C08.381.540.140.750 C08.785.520.100.220.750
|
Concept/Terms |
Small Cell Lung Carcinoma- Small Cell Lung Carcinoma
- Small Cell Lung Cancer
- Oat Cell Lung Cancer
- Small Cell Cancer Of The Lung
- Carcinoma, Small Cell Lung
- Oat Cell Carcinoma of Lung
|
Below are MeSH descriptors whose meaning is more general than "Small Cell Lung Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Small Cell Lung Carcinoma".
This graph shows the total number of publications written about "Small Cell Lung Carcinoma" by people in this website by year, and whether "Small Cell Lung Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 6 | 2 | 8 |
2010 | 7 | 1 | 8 |
2011 | 11 | 0 | 11 |
2012 | 4 | 2 | 6 |
2013 | 10 | 2 | 12 |
2014 | 6 | 1 | 7 |
2015 | 3 | 0 | 3 |
2016 | 7 | 0 | 7 |
2017 | 12 | 1 | 13 |
2018 | 20 | 0 | 20 |
2019 | 10 | 0 | 10 |
2020 | 16 | 1 | 17 |
2021 | 11 | 1 | 12 |
2022 | 6 | 0 | 6 |
2023 | 18 | 0 | 18 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Small Cell Lung Carcinoma" by people in Profiles.
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024 Mar 11; 42(3):429-443.e4.
-
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024 02 12; 42(2):225-237.e5.
-
Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Res. 2024 Jan; 44(1):133-137.
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
-
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Ann Oncol. 2024 Feb; 35(2):183-189.
-
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418.
-
Clinical Pharmacology Profile of AMG?119, the First Chimeric Antigen Receptor?T (CAR-T) Cell Therapy Targeting Delta-Like Ligand?3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). J Clin Pharmacol. 2024 Mar; 64(3):362-370.
-
Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies. Cancer Cell. 2023 09 11; 41(9):1535-1540.
-
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer. Clin Cancer Res. 2023 08 15; 29(16):3237-3249.
-
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours. Eur J Cancer. 2023 10; 192:113259.